Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $664,188.36 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the sale, the insider now owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Carmen Jeffrey Del also recently made the following trade(s):

• On Friday, June 7th, Carmen Jeffrey Del sold 7,541 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $16.07, for a total value of $121,183.87.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $19.91 on Friday. The firm’s 50 day moving average price is $16.33 and its two-hundred day moving average price is $15.70. The firm has a market cap of $2.35 billion, a PE ratio of 36.87 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.55 and a twelve month high of $19.98.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CPRX shares. Truist Financial lifted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Oppenheimer reissued an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright boosted their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $29.50.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently modified their holdings of CPRX. Boston Partners grew its stake in Catalyst Pharmaceuticals by 965.2% in the fourth quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock valued at $25,610,000 after purchasing an additional 1,396,930 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at approximately $805,000. Sei Investments Co. increased its holdings in Catalyst Pharmaceuticals by 64.3% in the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock worth $1,329,000 after buying an additional 32,621 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Catalyst Pharmaceuticals in the first quarter worth approximately $954,000. Finally, Vanguard Group Inc. raised its position in Catalyst Pharmaceuticals by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company’s stock valued at $119,694,000 after acquiring an additional 73,930 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.